Trial Profile
A Phase 2 Study of GW786034 (Pazopanib) in Patients With Recurrent and/or Metastatic Invasive Breast Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 13 May 2009 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Mar 2009 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
- 24 Apr 2008 The expected completion date for this trial is now 1 May 2008, according to ClinicalTrials.gov.